Key Takeaways
- • Dimension Capital closed an $800 million third fund, 60% larger than its $500 million second vehicle raised just 18 months prior, demonstrating robust institutional capital availability for science-compute intersection firms despite broader VC fundraising headwinds.
- • The firm's investment thesis has accelerated dramatically: Chai Discovery, a 2024 seed investment, raised $400 million at a $3.8 billion valuation in July 2026; New Limit, backed at Series A in January 2025, completed a Series C at $3.1 billion valuation in July 2026—both validating the deep-tech biotech-software convergence strategy.
- • Dimension Capital's portfolio benefits from strategic M&A exits: Anthropic acquired portfolio company Coefficient Bio (a drug discovery platform) for $400 million in spring 2026, granting Dimension equity positions in the high-profile AI firm.
- • Founded in late 2022 by Zavian Dar and Adam Goulburn (former Lux Capital partners) and Nan Li (Obvious Ventures alum), the four-year-old firm has established itself as a significant player in deep-tech venture despite the competitive fundraising environment for newer managers.
- • Notable portfolio holdings include Modal Labs (inference company) and Anthropic, alongside early-stage investments in AI-driven drug discovery and longevity startups, positioning Dimension at the nexus of AI commercialization and biotech innovation.
Summary
Dimension Capital announced the close of its third fund at $800 million on Tuesday, July 21, 2026, marking substantial momentum for the New York-based venture firm focused on the intersection of science and computational infrastructure. The fund is 60% larger than Dimension's second vehicle of $500 million, which closed just 18 months prior, signaling exceptional institutional confidence in the firm's thesis at a time when many emerging VC managers face capital constraints.
The firm was founded in late 2022 by three experienced venture professionals: Zavian Dar and Adam Goulburn, both formerly partners at Lux Capital, and Nan Li, an alumnus of Obvious Ventures. Their core investment thesis centers on founders building deep-tech companies that blur the boundaries between biotech and software—a convergence the partners believe is reshaping innovation. The rapid fund growth suggests this positioning has resonated strongly with limited partners.
Portfolio performance has validated Dimension's thesis with striking speed. Chai Discovery, which received a $30 million seed investment co-led by Dimension in 2024, announced a $400 million fundraise at a $3.8 billion valuation just last week. The startup develops open-source AI foundation models for drug development. Similarly, New Limit, an anti-aging company co-founded by Coinbase CEO Brian Armstrong and backed by Dimension at Series A in January 2025, completed a Series C this month at a $3.1 billion valuation. These rapid scaling events demonstrate strong market demand for AI-enabled biotech innovation.
Dimension's portfolio also includes Modal Labs, an inference infrastructure company, and a stake in Anthropic, the prominent AI research organization. The firm gained its Anthropic position when Anthropic acquired Dimension portfolio company Coefficient Bio, a drug discovery platform, for approximately $400 million in spring 2026. This acquisition exemplifies the firm's strategy of backing companies at the science-compute intersection while maintaining exposure to foundational AI infrastructure companies.
The firm was founded in late 2022 by three experienced venture professionals: Zavian Dar and Adam Goulburn, both formerly partners at Lux Capital, and Nan Li, an alumnus of Obvious Ventures. Their core investment thesis centers on founders building deep-tech companies that blur the boundaries between biotech and software—a convergence the partners believe is reshaping innovation. The rapid fund growth suggests this positioning has resonated strongly with limited partners.
Portfolio performance has validated Dimension's thesis with striking speed. Chai Discovery, which received a $30 million seed investment co-led by Dimension in 2024, announced a $400 million fundraise at a $3.8 billion valuation just last week. The startup develops open-source AI foundation models for drug development. Similarly, New Limit, an anti-aging company co-founded by Coinbase CEO Brian Armstrong and backed by Dimension at Series A in January 2025, completed a Series C this month at a $3.1 billion valuation. These rapid scaling events demonstrate strong market demand for AI-enabled biotech innovation.
Dimension's portfolio also includes Modal Labs, an inference infrastructure company, and a stake in Anthropic, the prominent AI research organization. The firm gained its Anthropic position when Anthropic acquired Dimension portfolio company Coefficient Bio, a drug discovery platform, for approximately $400 million in spring 2026. This acquisition exemplifies the firm's strategy of backing companies at the science-compute intersection while maintaining exposure to foundational AI infrastructure companies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.